These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27855351)

  • 1. Targeted therapy and elderly people: A review.
    Daste A; Chakiba C; Domblides C; Gross-Goupil M; Quivy A; Ravaud A; Soubeyran P
    Eur J Cancer; 2016 Dec; 69():199-215. PubMed ID: 27855351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.
    Howard SA; Rosenthal MH; Jagannathan JP; Krajewski KM; Shinagare AB; Ramaiya NH; Tirumani SH
    AJR Am J Roentgenol; 2015 May; 204(5):919-32. PubMed ID: 25905926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapy in Brain Metastases: Ready for Primetime?
    Venur VA; Ahluwalia MS
    Am Soc Clin Oncol Educ Book; 2016; 35():e123-30. PubMed ID: 27249714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Directed therapies in lung cancer: new hope?
    Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
    Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy in older patients with solid tumors.
    Kelly CM; Power DG; Lichtman SM
    J Clin Oncol; 2014 Aug; 32(24):2635-46. PubMed ID: 25071113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination of stereotactic irradiation and chemotherapy or targeted therapies: state of the art and preliminary recommendations].
    Thariat J; Kirova Y; Milano G; Mornex F
    Cancer Radiother; 2014; 18(4):270-9. PubMed ID: 25053603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
    Launay-Vacher V; Aapro M; De Castro G; Cohen E; Deray G; Dooley M; Humphreys B; Lichtman S; Rey J; Scotté F; Wildiers H; Sprangers B
    Ann Oncol; 2015 Aug; 26(8):1677-84. PubMed ID: 25735315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [MET receptor inhibition: Hope against resistance to targeted therapies?].
    Hochart A; Leblond P; Le Bourhis X; Meignan S; Tulasne D
    Bull Cancer; 2017 Feb; 104(2):157-166. PubMed ID: 27863726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.
    Gridelli C; Massarelli E; Maione P; Rossi A; Herbst RS; Onn A; Ciardiello F
    Cancer; 2004 Oct; 101(8):1733-44. PubMed ID: 15386339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy in metastatic renal cell cancer.
    Ravaud A; Gross-Goupil M; Bellmunt J
    Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II oncology trials: let's be positive.
    Ratain MJ
    Clin Cancer Res; 2005 Aug; 11(16):5661-2. PubMed ID: 16115898
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
    Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
    Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.
    Lombardi G; Di Stefano AL; Farina P; Zagonel V; Tabouret E
    Cancer Treat Rev; 2014 Sep; 40(8):951-9. PubMed ID: 24909312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
    Alimohamed N; Lee JL; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Tantravahi S; Kollmannsberger C; North S; Rini BI; Choueiri TK; Heng DY
    Clin Genitourin Cancer; 2014 Aug; 12(4):e127-31. PubMed ID: 24485801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy for solid tumors: current status.
    Zureikat AH; McKee MD
    Surg Oncol Clin N Am; 2008 Apr; 17(2):279-301, vii-viii. PubMed ID: 18375353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
    Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted agents in ovarian cancer.
    Kristedja TS; Morgan RJ; Cristea M
    Womens Health (Lond); 2010 Sep; 6(5):679-94. PubMed ID: 20887168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.